Early Detection and remediation
Decoding Dementia
About Ascento-CDA
Our Mission
At Ascento-CDA, our mission is to unlock the value of early detection in dementia and diabetes — two of the most costly and underdiagnosed conditions worldwide.
We developed IICM™ (Inflammatory, Immunologic & Cognitive Mapping) to help health providers and insurers:
- Identify high-risk patients earlier, before costly symptoms emerge
- Reduce avoidable spending, saving up to $100,000+ per patient over 10 years
- Create new revenue streams through risk reclassification and earlier interventions
By shifting detection into the pre-symptomatic “Golden Hour”, we deliver clinical impact and financial returns at scale.
Our Technology
Our proprietary platform, IICM™ (Inflammatory, Immunologic & Cognitive Mapping), is designed to uncover the active drivers of cognitive decline and diabetes at the earliest, often pre-symptomatic stages.
By combining cognitive testing to detect subtle brain function changes, biomarker analysis to reveal inflammatory and immunologic signals, and AI-driven mapping to correlate these patterns, IICM™ provides a level of insight that traditional tools consistently miss.
The result is a powerful ability to reclassify hidden risks — identifying patients incorrectly labeled as “low risk,” pinpointing underlying conditions that accelerate decline, and guiding clinicians toward timely, targeted interventions. This not only leads to better patient outcomes, but also creates measurable cost savings for insurers and new revenue opportunities for providers.
The Clinical Aspects
Our proprietary platform, IICM™ (Inflammatory, Immunologic & Cognitive Mapping), helps clinicians detect the active drivers of cognitive decline and diabetes at the earliest stages — often before symptoms appear.
By combining cognitive testing to identify subtle brain deficits, biomarker analysis to detect inflammatory patterns, and AI-driven mapping to correlate findings, IICM™ reveals risks that standard screening overlooks.
This allows physicians to reclassify patients more accurately, identify which underlying conditions may be accelerating decline, and make timely, targeted interventions that improve care quality and long-term outcomes.
Impact!
For Patients
IICM™ enables detection of cognitive decline and diabetes years earlier than conventional methods. By identifying risks and underlying conditions in the pre-symptomatic “Golden Hour,” patients gain access to timely interventions that can slow or prevent progression.
For Providers
Accurate risk reclassification creates opportunities for earlier-stage patient management and proactive interventions. This drives stronger engagement, supports chronic care programs, and ensures more effective use of medical resources.
For Insurers & Payviders
Earlier detection delivers significant and measurable savings by reducing late-stage treatment costs, avoiding preventable hospitalizations, and improving performance on key quality metrics.